EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity

Zengpeng Li, Mengyuan Li, Liu Yang, Jie Chen, Qian Ye, Wenbin Qian iD, Shibing Wang iD

Journal for ImmunoTherapy of Cancer · 2024-12 · 12 (12) · e009473

DOI: 10.1136/jitc-2024-009473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 22.12.2024. Verfasst von Zengpeng Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Third Institute of Oceanography Ministry of Natural Resources, Xiamen, China. Hauptthemen laut MEDLINE: CD47 Antigen, Vaccinia virus, Oncolytic Viruses, Oncolytic Virotherapy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Xiamen, China, Science Technology Department of Zhejiang Province, Science and Technology Planning Project of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Targeting CD47 for cancer immunotherapy has been studied in many clinical trials for the treatment of patients with advanced tumors. However, this therapeutic approach is often hampered by on-target side effects, physical barriers, and immunosuppressive tumor microenvironment (TME).

Methods

To improve therapeutic efficacy while minimizing toxicities, we engineered an oncolytic vaccinia virus (OVV) encoding an anti-CD47 nanobody (OVV-αCD47nb). We demonstrated the specific binding activity of αCD47nb secreted from the virus-infected cells to CD47 and that both secreted αCD47nb and OVV-αCD47nb blocked the “don’t eat me” signal of macrophages.

Results

Intratumorally injected OVV-αCD47nb continuously releases the αCD47nb in tumor tissues, thereby conferring superior systemic activity against breast and colon tumor cells and prolonging survival compared with OVV control. Furthermore, treatment with OVV-αCD47nb also remodeled the TME, as shown by increased T cell infiltration, CD8 + T cell activation and tumor-associated macrophages polarization, significantly enhancing innate and adoptive immunity. Additionally, the inclusion of programmed cell death protein-1 inhibiting boosted the anticancer efficacy of OVV-αCD47nb and raised the full response rate in tumor-bearing animals.

Conclusion

Overall, our findings highlight the therapeutic potential of OVV-αCD47nb for breast and colon cancer, and demonstrate its ability to modulate the immune cell profiles within tumors. This has established a rationale for further exploring OVV-αCD47nb as a potential therapy in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD47 AntigenVaccinia virusOncolytic VirusesOncolytic VirotherapyImmunity, InnateSingle-Domain AntibodiesNeoplasmsAnimalsMiceHumansFemaleTumor MicroenvironmentCell Line, Tumor

Stichwörter der Autor:innen

ImmunotherapyMacrophageOncolytic virus

Substanzen

CD47 AntigenSingle-Domain AntibodiesCD47 protein, human

Autor:innen und Institutionen

  • Third Institute of Oceanography Ministry of Natural Resources, Xiamen, China.
  • Department of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
  • Department of Medical Oncology, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Hangzhou Ronggu Biotechnology Limited Company, Hangzhou, China.
  • Hangzhou Ronggu Biotechnology Limited Company, Hangzhou, China wangshibing@hmc.edu.cn qianwb@zju.edu.cn yeqian@rongu-bio.com.
  • Department of Hematology, Zhejiang University, Hangzhou, Zhejiang, China wangshibing@hmc.edu.cn qianwb@zju.edu.cn yeqian@rongu-bio.com.

ORCID-Profile: Wenbin Qian, Shibing Wang

Förderung

  • Natural Science Foundation of Xiamen, China
  • Science Technology Department of Zhejiang Province
  • Science and Technology Planning Project of Fujian Province
  • National Natural Science Foundation of China
  • Xiamen Ocean and Fisheries Development Special Funds Program

Zitieren

APA

Li, Z., Li, M., Yang, L., Chen, J., Ye, Q., Qian, W., & Wang, S. (2024). Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity. Journal for ImmunoTherapy of Cancer, 12(12), e009473. https://doi.org/10.1136/jitc-2024-009473

Vancouver

Li Z, Li M, Yang L, Chen J, Ye Q, Qian W, et al. Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity. Journal for ImmunoTherapy of Cancer. 2024;12(12):e009473. doi:10.1136/jitc-2024-009473

BibTeX
@article{Li2024,
  author = {Li, Zengpeng and Li, Mengyuan and Yang, Liu and Chen, Jie and Ye, Qian and Qian, Wenbin and Wang, Shibing},
  title = {Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {12},
  pages = {e009473},
  doi = {10.1136/jitc-2024-009473}
}
Kostenlos starten →